Randomized Double-Blind Controlled Clinical Trial

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

February 1, 2022

Study Completion Date

March 1, 2022

Conditions
Chronic WoundsAcute Wounds
Interventions
DEVICE

AnaSept®

AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline. It has a broad-spectrum of antimicrobial action inhibiting the growth of Staphlyococcus aureus, Psuedomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, Clostridium difficile, including antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), Carbapenem Resistant E.coli (CRE) and Acinetobacter baumannii, that are commonly found in wound bed as well as fungi such as Candida albicans and Aspergillus niger. However, NaOCL is non-toxic to mammalian cells.

OTHER

NSS

NSS

Trial Locations (1)

15222

Serena Group Research Institute, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Anacapa Technologies Inc

UNKNOWN

lead

SerenaGroup, Inc.

NETWORK

NCT04320628 - Randomized Double-Blind Controlled Clinical Trial | Biotech Hunter | Biotech Hunter